Nephros Inc. (NASDAQ:NEPH) Short Interest Update

Nephros Inc. (NASDAQ:NEPH) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 3,625 shares, a decline of 49.9% from the November 30th total of 7,233 shares. Based on an average daily volume of 67,084 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 67,084 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

NEPH has been the topic of a number of analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Nephros in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Nephros to a “strong-buy” rating in a research report on Saturday, October 18th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.00.

Nephros Stock Performance

NASDAQ:NEPH traded up $0.01 during midday trading on Monday, reaching $4.94. 47,489 shares of the stock traded hands, compared to its average volume of 42,006. The stock has a market capitalization of $52.51 million, a P/E ratio of 38.00 and a beta of 1.48. The company has a fifty day moving average of $5.11 and a 200 day moving average of $4.47. Nephros has a 12 month low of $1.39 and a 12 month high of $6.42.

Nephros (NASDAQ:NEPH) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.05. The firm had revenue of $4.76 million for the quarter, compared to analysts’ expectations of $3.87 million. Nephros had a net margin of 8.26% and a return on equity of 15.81%.

Hedge Funds Weigh In On Nephros

Hedge funds and other institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC lifted its stake in Nephros by 39.2% in the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after acquiring an additional 4,655 shares during the period. Topline Capital Management LLC lifted its position in shares of Nephros by 24.9% in the 3rd quarter. Topline Capital Management LLC now owns 596,300 shares of the company’s stock worth $2,820,000 after purchasing an additional 118,851 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Nephros in the 3rd quarter worth about $64,000. Finally, Geode Capital Management LLC boosted its stake in shares of Nephros by 3.2% during the 2nd quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock valued at $381,000 after purchasing an additional 2,898 shares in the last quarter. Institutional investors own 41.10% of the company’s stock.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.